ABSTRACT
The journal Gastroentérologie clinique et biologique succeded to Archives des maladies de l'appareil digestif published since 1907 and is one of the world's oldest journals in gastroenterology. Gastroentérologie Clinique et Biologique was created as the discipline was emerging, benefiting from new techniques such as nasogastric intubation, coprologic examinations, the first images from gastrointestinal radiology, as well as the enormous progress made in gastrointestinal surgery. The journal was founded by Albert Mathieu, a remarkable chef d'école at Paris's Saint-Antoine Hospital. The journal showed rapid success, becoming the official organ of several learned societies, in particular the French National Society of Gastroenterology (Société nationale française de gastroentérologie [SNFGE]). Thoroughly updated in the 1970s, Gastroentérologie clinique et biologique has never ceased to evolve, adapting to technical and scientific upheavals, the globalization of knowledge, and the domination of the English language.
Subject(s)
Gastroenterology/history , Gastrointestinal Diseases/history , Periodicals as Topic/history , France , History, 20th Century , History, 21st Century , HumansABSTRACT
BACKGROUND: Visceral hypersensitivity plays a major role in irritable bowel syndrome pathophysiology. Opioid kappa receptors on afferent nerves may modulate it and be the target for new irritable bowel syndrome treatments. AIM: This study evaluated the effect of the kappa opioid agonist asimadoline on perception of colonic distension and colonic compliance in irritable bowel syndrome patients. METHOD: Twenty irritable bowel syndrome female patients (Rome II criteria; 40 +/- 13 years) and hypersensitivity to colonic distension (Pain threshold < or = 32 mmHg) were included in a randomized double-blind cross-over trial comparing the effect of a single oral dose of asimadoline 0.5 mg or placebo on sensory thresholds (defined as a constant and sustained sensation) elicited by left colon phasic distension (5 mmHg steps, 5 min) up to a sensation of abdominal pain. Colonic compliance was compared by the slope of the pressure-volume curves. RESULTS: On asimadoline, pain threshold (mean +/- s.d.) (29.8 +/- 7.2 mmHg) was higher than on placebo (26.3 +/- 7.8 mmHg), difference not statistically significant (P = 0.1756, ANOVA). Area under curve of pain intensity rated at each distension step was significantly lower on asimadoline (89.3 +/- 33.9, ANOVA) than on placebo (108.1 +/- 29.7) (P = 0.0411). Thresholds of perception of nonpainful distensions were not altered on asimadoline, as compared with placebo. Colonic compliance was not different on placebo and asimadoline. CONCLUSION: Asimadoline decreases overall perception of pain over a wide range of pressure distension of the colon in irritable bowel syndrome patients, without altering its compliance. These data suggest that further studies should explore the potential benefit of asimadoline in treatment of pain in irritable bowel syndrome patients.
Subject(s)
Acetamides/therapeutic use , Irritable Bowel Syndrome/drug therapy , Narcotic Antagonists/therapeutic use , Pain/prevention & control , Pyrrolidines/therapeutic use , Administration, Oral , Adolescent , Adult , Aged , Dilatation/methods , Double-Blind Method , Female , Humans , Irritable Bowel Syndrome/pathology , Middle Aged , Pain Measurement , Pain Threshold , PressureABSTRACT
BACKGROUND: The impact of irritable bowel syndrome (IBS) on health-care resource use in France is evaluated, and explanatory variables determined. METHODS: A questionnaire comprising socio-demographic characteristics, symptoms, consumption of resources, quality of life and impact of IBS on productivity was administered by telephone to a sample of 253 French adults with IBS recruited from the general population, and diagnosed with IBS using several well-known diagnostic criteria. The medical costs were estimated on a monthly basis and included medication(s), physicians' consultations, investigations and hospitalizations. RESULTS: Mean age was 48.3 years and 75% of subjects were women (192). Thirty-six percent of subjects had suffered from IBS for more than 10 years; 77% had consulted a general practitioner and 43% a gastroenterologist. Twenty-nine percent of subjects had undergone an investigation and 25% reported hospitalization; 61% of patients reported that they were taking medication. The average monthly medical costs was 71.8 euros (95% CI = [57.6-86.0]) with an asymmetric distribution (median = 28.1 euros) because of a high proportion of subjects (27%) who reported receiving no care at all. The two principal cost components were investigations (39%), and hospitalizations (22%). The highest medical costs were associated with subjects who were very elderly or suffered from severe symptoms (very severe pain), and were correlated with the lowest quality of life scores. CONCLUSION: IBS has a major impact on resource consumption and the productivity of patients. Determination of the variables to explain medical costs showed that advanced age, severe pain and deterioration in quality of life could be predictive of high medical costs.
Subject(s)
Absenteeism , Cost of Illness , Health Care Costs , Irritable Bowel Syndrome/economics , Adolescent , Adult , Aged , Aged, 80 and over , Female , France , Health Care Surveys , Humans , Irritable Bowel Syndrome/psychology , Male , Middle Aged , Quality of Life/psychologyABSTRACT
BACKGROUND: Rectal sensory thresholds are lowered in patients with irritable bowel syndrome (IBS), reflecting visceral hyperlagesia, which might be related to subclinical inflammation. AIM: To evaluate the effects of an intraluminal injection of glycerol, a mucosal irritant, on rectal tone and perception of distension in 12 healthy subjects. METHODS: Rectal tone was evaluated with a barostat. First sensation, need to defecate and pain thresholds were evaluated during isobaric phasic distensions, before and 20 and 120 min after injection of 10 ml glycerol in the rectum. RESULTS: Baseline bag volume (97.9 +/- 56.2 ml) significantly decreased 20 min (49.7 +/- 42.2 ml; P= 0.026) and 120 min (66.5 +/- 38.3 ml; P= 0.050) after injection of glycerol, indicating its hypertonic effect. The pressure defining sensory thresholds was decreased significantly 20 min after glycerol injection: first sensation, 14.6 +/- 2.9 versus 18.3 +/- 7.2 mm Hg (P = 0.01); need to defecate, 19.6 +/- 3.7 versus 26.0 +/- 6.9 mm Hg; pain, 23.8 +/- 4.5 versus 35.6 +/- 9.5 mm Hg (P = 0.001). This effect was maintained for 120 min after injection of glycerol. Slopes of the compliance curves did not differ before and after injection of glycerol. CONCLUSIONS: Intraluminal injection of glycerol significantly increases rectal tone and sensitizes healthy volunteers to rectal distension, since they show significantly lower thresholds after glycerol. This could constitute a model of visceral hypersensitivity in healthy volunteers.
Subject(s)
Glycerol/administration & dosage , Glycerol/pharmacology , Rectum/drug effects , Administration, Rectal , Adult , Biopsy , Defecation , Humans , Intestinal Mucosa/drug effects , Intestinal Mucosa/metabolism , Intestinal Mucosa/pathology , Male , Nitric Oxide/metabolism , Pain Threshold , Rectum/metabolism , Rectum/pathology , Rectum/physiology , Reference ValuesSubject(s)
Colonic Diseases, Functional/physiopathology , Adult , Animals , Antidepressive Agents/administration & dosage , Antidepressive Agents/therapeutic use , Antidepressive Agents, Second-Generation/administration & dosage , Antidepressive Agents, Second-Generation/therapeutic use , Antidepressive Agents, Tricyclic/administration & dosage , Antidepressive Agents, Tricyclic/therapeutic use , Benzyl Compounds/administration & dosage , Benzyl Compounds/therapeutic use , Biopsy , Colon/pathology , Colonic Diseases, Functional/diet therapy , Colonic Diseases, Functional/drug therapy , Colonic Diseases, Functional/etiology , Colonic Diseases, Functional/pathology , Colonic Diseases, Functional/psychology , Diarrhea/etiology , Electromyography , Female , Fluoxetine/administration & dosage , Fluoxetine/therapeutic use , Food Hypersensitivity/complications , Gastrointestinal Motility , Guinea Pigs , Humans , Ileum/pathology , Imipramine/administration & dosage , Imipramine/therapeutic use , Inflammation , Male , Mental Disorders/complications , Propylamines/administration & dosage , Propylamines/therapeutic use , Psychotherapy , Psychotropic Drugs/administration & dosage , Psychotropic Drugs/therapeutic use , Rats , Selective Serotonin Reuptake Inhibitors , Sex Offenses , Time FactorsSubject(s)
Central Nervous System/physiology , Colonic Diseases, Functional/drug therapy , Colonic Diseases, Functional/physiopathology , Abdominal Pain/etiology , Animals , Benzyl Compounds/administration & dosage , Benzyl Compounds/therapeutic use , Carbolines/administration & dosage , Carbolines/therapeutic use , Colitis, Ulcerative/complications , Colon/innervation , Colon/physiopathology , Colonic Diseases, Functional/diagnosis , Colonoscopy , Controlled Clinical Trials as Topic , Diarrhea/etiology , Diarrhea/physiopathology , Digestion , Electromyography , Female , Follow-Up Studies , Gastric Emptying , Gastroenteritis/complications , Gastrointestinal Agents/administration & dosage , Gastrointestinal Agents/therapeutic use , Gastrointestinal Motility , Humans , Indoles/administration & dosage , Indoles/therapeutic use , Intestines/innervation , Male , Myenteric Plexus/physiology , Neurons/physiology , Neurotransmitter Agents/physiology , Neurotransmitter Agents/therapeutic use , Placebos , Pressure , Propylamines/administration & dosage , Propylamines/therapeutic use , Receptors, Opioid, kappa/agonists , Rectum/innervation , Rectum/physiopathology , Risk Factors , Serotonin Antagonists/administration & dosage , Serotonin Antagonists/therapeutic use , Serotonin Receptor Agonists/administration & dosage , Serotonin Receptor Agonists/therapeutic use , Sex Factors , Time FactorsSubject(s)
Splenic Diseases/diagnosis , Splenic Infarction/diagnosis , Adult , Female , Humans , Splenic Diseases/diagnostic imaging , Splenic Diseases/pathology , Splenic Infarction/diagnostic imaging , Splenic Infarction/pathology , Syndrome , Tomography, X-Ray Computed , Torsion Abnormality , Ultrasonography, DopplerABSTRACT
BACKGROUND: Endoscopic ultrasonography (EUS) is highly accurate for the staging of tumors, but its role in the management of periampullary carcinoma is still being defined. METHODS: Seventy-nine patients with pancreatic (n = 73) or ampullary (n = 6) carcinoma underwent prospective evaluation by means of assessment of resectability and survival according to the following three-step staging algorithm: (1) ultrasonography and computed tomography; (2) if tumor appears resectable, EUS; (3) if criteria of resectability are found at EUS, laparotomy for curative resection. RESULTS: The first step of the algorithm helped predict unresectability of tumors and need for palliative treatment for 36 patients. Among the other 43 patients EUS revealed signs of unresectability in 20 additional patients who then underwent palliative surgical or medical treatment (median survival time 7 to 8 months). Twenty-three carcinomas were considered resectable according to EUS findings: Palliative surgery was performed in 9 cases (survival time 6 months), and 14 tumors could be resected in a curative way with a median survival period of 15 (pancreatic) to 16 months (ampullary). In evaluation of resectability, EUS had a 50% sensitivity (positive examination), 100% specificity, 100% positive predictive value, 61% negative predictive value, and 72% accuracy. CONCLUSIONS: EUS is accurate for evaluating resectability of ampullary and pancreatic cancer. EUS staging can prevent unnecessary surgery, and the findings correlate well with prognosis. The management of ampullary and pancreatic cancer could be improved with EUS.
Subject(s)
Ampulla of Vater/diagnostic imaging , Carcinoma/diagnostic imaging , Common Bile Duct Neoplasms/diagnostic imaging , Endosonography , Pancreatic Neoplasms/diagnostic imaging , Adult , Aged , Aged, 80 and over , Algorithms , Ampulla of Vater/surgery , Carcinoma/mortality , Carcinoma/surgery , Common Bile Duct Neoplasms/mortality , Common Bile Duct Neoplasms/surgery , Female , Humans , Male , Middle Aged , Palliative Care , Pancreatic Neoplasms/mortality , Pancreatic Neoplasms/surgery , Prognosis , Prospective Studies , Reproducibility of Results , Sensitivity and Specificity , Survival RateABSTRACT
Hypersensitivity to rectal distension is frequently observed in patients with irritable bowel syndrome (IBS). However, few data are available about the influence of age on rectal sensory thresholds and tone. The aim of this study was to measure rectal sensory thresholds and tone with a barostat in 12 healthy subjects (aged 86 +/- 4 years, eight females, four males) as compared with 12 young healthy male controls (26 +/- 1 years). Isobaric phasic distensions were performed in the fasted state (increment of 4 mmHg, steps of 5 min, interval of 5 min). Rectal tone changes were then measured as changes in volume of the barostat bag, the pressure being kept constant. After a baseline recording of 1 h, a 1000-kcal meal was served and the tone recorded until return to baseline. Rectal sensory thresholds were significantly higher in aged subjects. First sensation, sensation of urge to defaecate and sensation of pain were triggered at 21.1 +/- 3.2 mmHg, 30.4 +/- 5.4 mmHg and 40.5 +/- 5.0 mmHg, respectively, in aged subjects, vs 13.3 +/- 4.6 mmHg (P < 0.05), 20.7 +/- 1.0 mmHg (P < 0.001) 31.3 +/- 1.7 mmHg (P < 0.001) in controls. Rectal compliance was not significantly different between the two groups. Mean barostat bag volume was 104 +/- 13 mL in fasting aged subjects and 125 +/- 23 mL in controls (NS). After the meal, the barostat bag volume decreased by 69 +/- 11% during 85 +/- 17 min in aged subjects and 75 +/- 14% during 89 +/- 15 min in young controls (NS). Rectal sensory thresholds triggered by distension are increased in aged healthy subjects while compliance and tone are not different. Age should be considered as a confounding factor when studying rectal sensitivity and further studies in aged patients with IBS should include a group of control subjects within the same range of age as studied patients.
Subject(s)
Aging/physiology , Colonic Diseases, Functional/physiopathology , Muscle Tonus/physiology , Rectum/physiology , Adult , Aged , Aged, 80 and over , Case-Control Studies , Female , Humans , Male , Reference Values , Sensory Thresholds/physiologyABSTRACT
Irritable bowel syndrome (IBS) is characterized by a number of clinical features and probably comprises a cluster of different conditions. The most frequent symptom reported by IBS patients is abdominal pain, although for a number of patients, bowel disturbances are the most prominent symptoms. Diarrhetic patients are seen in referral centres in continental Europe less frequently than in the United Kingdom or the United States. On the contrary, patients with constipation-prone IBS may comprise up to 80% of the IBS population referred to these centres. The pathophysiology of IBS is based on multiple factors. Most of the therapeutics proposed for the management of patients with IBS have been developed on the assumption that motility disorders of the gut are the most reliable pathological findings among these patients. Consequently, antispasmodics and motility regulatory agents have been widely used, alone or in association with intestinal adsorbents (clay-derived preparations), and laxatives or antidiarrhetic agents. Most of these drugs were developed several decades ago, and studies showing their efficacy have not reached the level of quality that is now required of randomized controlled trials. Therefore, following a complete and detailed review published in 1989, these drugs have not been used extensively in the United Kingdom or the United States. Large inquiries have also shown that the duration of prescription is quite different among countries. In European countries, maintenance therapy is frequently prescribed for several weeks to attempt to decrease the number of acute episodes. In contrast, psychotropic drugs are less popular among European gastroenterologists than among American gastroenterologists. However, multidisciplinary approaches to the treatment of these patients are frequent, and such drugs are often prescribed by home physicians. The results of large surveys estimated the yearly cost of such treatments to be around US$850. Patients with constipation and elderly patients with chronic disease receive more expensive treatments.
Subject(s)
Colonic Diseases, Functional/drug therapy , Abdominal Pain/drug therapy , Colonic Diseases, Functional/economics , Colonic Diseases, Functional/physiopathology , Cost of Illness , Europe , Humans , Practice Patterns, Physicians'ABSTRACT
BACKGROUND & AIMS: Visceral hypersensitivity plays a major role in the pathophysiology of inflammatory bowel syndrome (IBS). Opioid kappa receptors on afferent nerves may modulate it and may be the target of new IBS treatments. The aim of this study was to evaluate the effects of fedotozine, a potent and selective kappa agonist, on responses to colonic distention and colonic compliance in patients with IBS. METHODS: Fourteen patients with IBS (Rome criteria; 50 +/- 12 years; 6 men and 8 women) were included in a randomized double-blind, crossover trial comparing the effect of an intravenous infusion of 100 mg fedotozine or saline on sensory thresholds elicited by left colon phasic distention (4-mm Hg steps for 5 minutes) up to a sensation of abdominal pain. Colonic compliance was compared by the slope of the pressure-volume curves built on placebo and on fedotozine. RESULTS: In the fedotozine group, thresholds of first perception (28.7 +/- 5.9 mm Hg) and pain (34.7 +/- 5.5 mm Hg) were significantly greater than with placebo (23.3 +/- 4.5 and 29.0 +/- 3.5 mm Hg, respectively; P = 0.0078). Colonic compliance was 9. 20 +/- 3.87 mL. mm Hg-1 with placebo and 8.73 +/- 3.18 mL. mm Hg-1 with fedotozine (not significant). CONCLUSIONS: Fedotozine increases thresholds of perception of colonic distention in patients with IBS without modifying colonic compliance. Fedotozine seems capable of reversing visceral hypersensitivity observed in these patients and could have some beneficial action on their symptoms.
Subject(s)
Benzyl Compounds/therapeutic use , Colon/drug effects , Colonic Diseases, Functional/drug therapy , Propylamines/therapeutic use , Receptors, Opioid, kappa/agonists , Adult , Benzyl Compounds/administration & dosage , Colon/physiopathology , Colonic Diseases, Functional/physiopathology , Cross-Over Studies , Double-Blind Method , Eating , Female , Humans , Infusions, Intravenous , Male , Manometry , Middle Aged , Pain Threshold/drug effects , Propylamines/administration & dosage , Sensory Thresholds/drug effectsABSTRACT
Distension of the small intestine can play a role in the pathogenesis of various functional intestinal disorders. This study determined the role of vasoactive intestinal polypeptide (VIP) in the adaptative response of intestinal smooth muscle to acute and chronic distension of the ileum in vivo. Several in vitro experiments were performed to identify the mechanism of receptor regulation. Distension was applied by a balloon inflated with air in the ileum either during a single episode in anesthetized or repeatedly in conscious guinea pigs. Then, muscle cells were isolated by enzymatic digestion from the distended and nondistended adjacent ileal segments. In addition, in vitro experiments were performed on freshly dispersed cells for determination of mechanisms. Control cells maximally relaxed (Cmax) at 1 microM VIP (EC50 = 50 pM) and 100 microM isoproterenol (EC50 = 7 nM). Both acute and chronic distensions triggered a right-ward shift of the concentration-response curves for VIP (Cmax = 100 microM, EC50 = 10 nM). A desensitization of the relaxing effect of VIP receptors was also observed when cells were preincubated for 30 min in vitro with VIP. By contrast, the relaxing effect of isoproterenol was affected neither by in vivo distension nor by in vitro incubation with isoproterenol. Desensitization of VIP receptors was prevented by in vitro incubation of cells with VIP plus a VIP antagonist [(D-P-Cl-Phe6,Leu17)VIP] and by intraluminal perfusion of the VIP antagonist during acute distention in vivo. Moreover, desensitization of VIP receptors did not occur after 30 min preincubation with either forskolin or 8-Bromo-cyclic AMP. These results indicate that mechanical distension of the ileum induces a homologous desensitization of VIP receptors on circular smooth muscle cells, which requires the occupation of its receptors by VIP.
Subject(s)
Muscle, Smooth/drug effects , Stress, Mechanical , Vasoactive Intestinal Peptide/pharmacology , 8-Bromo Cyclic Adenosine Monophosphate , Adaptation, Physiological/drug effects , Animals , Cell Separation , Colforsin , Guinea Pigs , Ileum/drug effects , In Vitro Techniques , Intestinal Diseases/etiology , Isoproterenol/pharmacology , Male , Muscle Contraction/drug effects , Muscle, Smooth/cytology , Muscle, Smooth/physiology , Receptors, Vasoactive Intestinal Peptide/metabolism , Sincalide/pharmacology , Vasoactive Intestinal Peptide/antagonists & inhibitorsABSTRACT
AIM: To determine the kinetics of platelet activating factor (PAF) and prostaglandin E2 (PGE2) receptor desensitisation during intestinal inflammation induced by trinitrobenzenesulphonic acid (TNB) instillation and to study the relation between receptor regulation, inflammatory lesions, and PAF content of the gut wall. METHODS: Receptor desensitisation was assessed on isolated smooth muscle cells from the circular layer. PAF content of the intestinal wall was determined by thin layer chromatography and radioimmunoassay. RESULTS: After an acute inflammatory phase on day 1, subacute changes appeared in TNB instilled ileum, with a maximal intensity on day 6. In control animals, PAF 10 nM and PGE2 10 nM provoked a maximal contraction in the range of 24% of cell shortening. On days 1 and 3 after intestinal instillation of TNB, PAF induced contraction was not altered whereas the effect of PGE2 was progressively desensitised (2 logM rightward shift of its concentration-response curve: Cmax = 1 microM; p < 0.01). Between days 4 and 6, the concentration-response curve of PGE2 shifted by only 1 logM (p < 0.05) whereas the curve of PAF induced contraction shifted by 2 logM (Cmax = 1 microM; p < 0.01). The PAF content of the ileal wall was maximal between days 3 and 5 (300 ng/mg tissue). On days 10 and 15, PAF and PGE2 induced contractions were similar to those observed on day 1, and PAF content returned to basal. CONCLUSION: Inflammation induced by TNB instillation triggers PAF and PGE2 receptor desensitisation; this is dependent on the duration of inflammation and correlates with PAF content in the ileum. This receptor desensitisation may play a protective role by preventing overstimulation of intestinal smooth muscle cells.
Subject(s)
Ileitis/metabolism , Ileum/metabolism , Platelet Activating Factor/pharmacology , Platelet Membrane Glycoproteins/drug effects , Receptors, Cell Surface , Receptors, G-Protein-Coupled , Acetylcholine/pharmacology , Animals , Cell Size/drug effects , Cholecystokinin/pharmacology , Dinoprostone/metabolism , Dinoprostone/pharmacology , Dose-Response Relationship, Drug , Guinea Pigs , Ileitis/immunology , Ileitis/pathology , Ileum/immunology , Ileum/pathology , Male , Muscle Contraction/drug effects , Muscle, Smooth/drug effects , Platelet Activating Factor/analysis , Platelet Activating Factor/metabolism , Platelet Membrane Glycoproteins/metabolism , Receptors, Prostaglandin E/drug effects , Receptors, Prostaglandin E/metabolism , Stimulation, Chemical , Time Factors , Trinitrobenzenesulfonic AcidABSTRACT
UNLABELLED: To study the prevalence of "reported" functional digestive symptoms (FDS) in terms easily understood by the general population without resorting to predefined concepts of functional syndromes, and to assess FDS impact on public health, a sample survey has been carried out between September and December 1995. METHODS: Four thousand eight hundred and seventeen subjects representative of the French general population aged 15 years or more filled in a questionnaire describing their digestive disorders. RESULTS: Seventy percent of the subjects had digestive complaints, 9% being related to a presumably organic disease, and 61% attributed to FDS. Twenty-seven % of the subjects claimed to be inconvenienced by their FDS, whereas 34% seemed not to feel any inconvenience. Among FDS, gas emission was the most frequent symptom (59%), followed by stomach ache and/or digestive pain (48%), flatulence (47%), bad digestion sensations (40%), constipation (35%), aerophagia (29%), bad breath (22%), incomplete evacuation of stools (19%). FDS had lasted from 6 months to 5 years in 38%, and over 5 years in 52%. In the subgroup of subjects inconvenienced by FDS (27%), 9% consulted and 18% did not, whereas in the subgroup not inconvenienced, 3% consulted and 31% did not. Altogether, 26% of the subjects followed a prescription or self medication treatment; 35% were not treated. Some explanatory variables appeared to be associated with the onset of inconvenience: the associations pain and bad digestion, flatulence and aerophagia, incomplete evacuation and nervous or presumably organic origin of FDS, age, stress, FDS frequency. Duration of symptoms, age above 65 years, digestive pain, presumably organic origin, and FDS frequency were associated with the need to consult. This descriptive, pragmatic survey shows the widespread prevalence of FDS, affecting 28 million French people. Functional digestive disorders in the "academic" meaning constitute only a limited subset. FDS lead to major health care consumption. Their impact on public health is undoubtedly greater than the estimates derived from studies designed in accordance with conventional nosological categories.
Subject(s)
Digestive System Diseases/epidemiology , Population Surveillance , Adolescent , Adult , Aged , Demography , Digestive System Diseases/drug therapy , Female , France/epidemiology , Humans , Male , Middle Aged , Prevalence , Surveys and QuestionnairesABSTRACT
BACKGROUND: Visceral hypersensitivity plays a major role in the pathophysiology of irritable bowel syndrome, as shown by balloon distension studies. 5-HT3 receptors on afferent nerves may modulate visceral sensitivity and be the target of new treatments for irritable bowel syndrome. AIM: To evaluate the effects of alosetron, a potent and selective 5-HT3 antagonist, on the perception of colonic distension by patients with irritable bowel syndrome, and on the colonic compliance to distension with a barostat. METHODS: Twenty-five irritable bowel syndrome patients were included in a randomized double-blind parallel group trial; data were available for 22 (Rome criteria; 48 +/- 11 years: 13 men and nine women). Patients were treated for 7 days with placebo (n = 6), alosetron 0.25 mg b.d. (n = 8) or alosetron 4 mg b.d. (n = 8). On day 6, a barostat bag was placed in the left colon. On day 7, after an overnight fast, isobaric phasic distensions were performed (4 mmHg steps, 5 min) up to the step triggering a sensation of abdominal pain. RESULTS: Groups were comparable at inclusion (age, sex, symptoms, bowel habits). There were no differences between treatment groups in pressure recorded within the bag at the time of first sensation of abdominal pain. However, bag volumes were significantly increased. At the first sensation threshold, median volume differences of 61 mL and 90 mL (P = 0.028) were recorded with alosetron 0.25 mg b.d. and 4 mg b.d., respectively. At the threshold of abdominal pain, these differences were 71 mL (P = 0.039) and 84 mL (P = 0.017). Colonic compliance increased from 5.9 mL/mmHg on placebo to 7.6 mL/mmHg on alosetron 0.25 mg b.d. and to 9.8 mL/mmHg (P = 0.034) on alosetron 4 mg b.d. CONCLUSION: Alosetron increases the compliance of the colon to distension, and could thereby contribute to changes in perception of colonic distension and improvement in the symptoms of irritable bowel syndrome.
Subject(s)
Carbolines/therapeutic use , Colon/drug effects , Colonic Diseases, Functional/drug therapy , Serotonin Antagonists/therapeutic use , Adult , Colon/physiology , Colonic Diseases, Functional/physiopathology , Compliance , Double-Blind Method , Female , Humans , Male , Middle Aged , Pain Threshold/drug effects , Pelvic Pain/drug therapy , Perception/drug effectsABSTRACT
Over the last decade, the role of visceral sensitivity has been largely recognized in the pathophysiology of functional digestive disorders, particularly in the irritable bowel syndrome. These studies have highlighted the role of afferent pathways arising from the gut as a possible target for new treatments intended to relieve pain or modify altered reflexes present in such patients. These pharmacological targets have been identified mainly by studies on animal models of visceral hyperalgesia of various origins including local inflammation. Locally, several mediators are of paramount importance for sensitization of nerve endings: 5-hydroxytryptamine, bradykinin, tachykinins, calcitonin gene-related peptide, and neurotrophins. Selective antagonists to various subtypes of their receptors are currently available and have been shown to be active in these animal models. Other substances, such as somatostatin, opiold peptides, cholecystokinin, oxytocin, and adenosine, modulate the transmission of nociceptive inputs from the gut to the brain and are of clinical interest. This article reviews the current understanding of these mediators. Although these agents seem to be promising tools for the treatment of visceral hyperalgesia and its consequences (abdominal pain and disturbed reflexes), their clinical efficacy remains to be shown. A better understanding of the nature and the location of the defect in the sensory pathways may permit the selection of subgroups of patients for treatment according to the pharmacological properties of these new therapeutic agents.
Subject(s)
Gastrointestinal Diseases/physiopathology , Sensation/physiology , Viscera/physiopathology , Animals , Gastrointestinal Diseases/diagnosis , Humans , Hyperalgesia/physiopathology , Inflammation/physiopathology , Nervous System/physiopathology , Sensation/drug effectsABSTRACT
Exocrine pancreas from different species behaves differently in response to the presence of intact or digested nutrients in the duodenum. A failure of cholecystokinin (CCK) release after a meal has been shown among patients with exocrine pancreatic insufficiency. This abnormality could be restored by the administration of pancreatic extracts, suggesting that digested rather than intact nutrients are responsible for the release of CCK and subsequently gallbladder contraction in humans. The aim of this study was to determine the specific role of different lipidic stimuli in humans. Seven male patients (mean age, 52 years) with pancreatic insufficiency secondary to chronic pancreatitis were selected. Pancreatic insufficiency was considered severe in five of them (lipase output, < 1,000 IU/min) and moderate in another two (lipase output, > 1,000 and < 2,300 IU/min). Plasma CCK (by bioassay), gallbladder contraction (by ultrasound), and enzyme output (chymotrypsin) in response to duodenal administration of either oleic acid as free fatty acids or 20% Intralipid as triglycerides were measured in each patient with at least a 48-h interval between each test. In all these patients with pancreatic insufficiency, duodenal perfusion of free fatty acids generated a more pronounced (91 +/- 11 vs. 49 +/- 21 pM) and faster (15 vs. 30 min) (p < 0.05) CCK release than triglycerides. Furthermore, gallbladder contraction was more efficient when free fatty acids instead of triglycerides were administered in the duodenum (86 +/- 5 vs. 69 +/- 4%) at 10 min (p < 0.05) and (73 +/- 8 vs. 51 +/- 5%) at 15 min (p < 0.03). Among patients with measurable residual pancreatic function, enzyme outputs were shown to be higher during free fatty acid than triglyceride perfusion. In humans, free fatty acids rather than triglycerides, when present in the duodenum, stimulate CCK release and gallbladder contraction. In patients with moderate pancreatic insufficiency this phenomenon may increase residual enzymatic secretion. These results allow us to encourage the development of enzymatic preparations as acid-resistant lipases that cause a fast release of free fatty acids in the duodenum.
Subject(s)
Cholecystokinin/metabolism , Duodenum/metabolism , Fatty Acids, Nonesterified/physiology , Triglycerides/physiology , Adult , Aged , Gallbladder/physiology , Humans , Male , Middle Aged , Muscle ContractionABSTRACT
The direct effects and the intracellular pathways of rCGRP were investigated on smooth muscle cells (SMC) isolated by enzymatic digestion from the circular and longitudinal layers of guinea-pig ileum. In circular SMC, rCGRP inhibited CCK8-induced contraction in a concentration-dependent manner (Cmax = 100 microM and EC50 = 0.7 +/- 0.4 nM). Preincubation of SMC with 1 microM Rp-cAMPs, a cAMP antagonist, abolished the relaxing effect of rCGRP; moreover, preincubation of SMC with 100 microM L-NAME, an inhibitor of NOS, inhibited the relaxing effect of rCGRP, hCGRP(8-37), a selective antagonist of rCGRP receptors, inhibited the rCGRP-induced relaxation in a concentration dependent manner whereas the vasoactive intestinal polypeptide (VIP) antagonist had no significant effect. In longitudinal SMC, rCGRP-induced relaxation was abolished by Rp-cAMPs, whereas L-NAME had no effect. In conclusion, rCGRP triggers different intracellular pathways to induce relaxation of circular or longitudinal intestinal SMC; cAMP is involved in cells from both layers while nitric oxide (NO) is involved only in relaxation of circular SMC.
Subject(s)
Calcitonin Gene-Related Peptide/pharmacology , Cyclic AMP/metabolism , Ileum/drug effects , Muscle Relaxation/drug effects , Muscle, Smooth/drug effects , Nitric Oxide/metabolism , Animals , Arginine/pharmacology , Calcitonin Gene-Related Peptide Receptor Antagonists , Cyclic AMP/analogs & derivatives , Cyclic AMP/antagonists & inhibitors , Cyclic AMP/pharmacology , Guinea Pigs , Ileum/physiology , In Vitro Techniques , Muscle Contraction/drug effects , Muscle, Smooth/physiology , NG-Nitroarginine Methyl Ester/pharmacology , Nitric Oxide/antagonists & inhibitors , Peptide Fragments/pharmacology , Recombinant Proteins/pharmacology , Sincalide/antagonists & inhibitors , Sincalide/pharmacology , Thionucleotides/pharmacology , Vasoactive Intestinal Peptide/antagonists & inhibitorsABSTRACT
AIM: The effects of oxytocin on colonic perception of intraluminal distension were evaluated in 26 patients with irritable bowel syndrome (IBS), using a flaccid bag placed in the descending colon and connected to a computerised barostat. METHOD: Symptomatic responses (first sensation and pain) were evaluated during isobaric distensions (4 mm Hg increments, five minute duration, five minute interval with return to zero pressure between each step), performed automatically by the barostat, during a continuous infusion of placebo or various doses of oxytocin (10, 20, 30, and 50 mU/min). RESULTS: The distension pressure (mean (SD)) required to induce a first abdominal sensation was 17.3 (5.5) mm Hg on placebo, 19.9 (5.8) on oxytocin 10 mU/min (NS), 22.3 (6.0) mm Hg on oxytocin 20 mU/min (p < 0.01), 23.1 (6.6) mm Hg on oxytocin 30 mU/min (p < 0.01), and 24.0 (7.1) mm Hg on oxytocin 50 mU/min (p < 0.01). The distension pressure required to induce pain was 24.8 (6.3) mm Hg on placebo, 26.0 (5.8) on oxytocin 10 mU/min (NS), 33.3 (7.8) mm Hg on oxytocin 20 mU/min (p < 0.01), 34.2 (7.6) mm Hg on oxytocin 30 mU/min (p < 0.01), and 34.3 (7.9) mm Hg on oxytocin 50 mU/ min (p < 0.01). Compliance curves were not different after placebo and oxytocin injection at the different doses. Naloxone did not inhibit the effect of oxytocin. Oxytocin also did not alter somatic perception, characterised by the RIII reflex at the level of the biceps femori. CONCLUSIONS: Oxytocin significantly increases thresholds for visceral perception in IBS patients at doses equal or to greater than 20 mU/min, possibly by acting at the level of visceral afferents.